***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: The Global Asthma Network ( GAN ) , established in 2012 , followed the International Study of Asthma and Allergies in Childhood ( ISAAC ) . ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries ; it found marked worldwide variation in symptom prevalence of asthma , rhinitis and eczema that was not explained by the current underst and ing of these diseases ; ISAAC Phase Three involved over 1 187 496 adolescents and children ( 237 centres in 98 countries ) . It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high , and identified several environmental factors that required further investigation . GAN Phase I , described in this article , builds on the ISAAC findings by collecting further information on asthma , rhinitis and eczema prevalence , severity , diagnoses , asthma emergency room visits , hospital admissions , management and use of asthma essential medicines .  The subjects will be the same age groups as ISAAC , and their parents . In this first global monitoring of asthma in children and adults since 2003 , further evidence will be obtained to underst and asthma , management practice s and risk factors , leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden . The Global Asthma Network undertakes global studies of asthma surveillance , management and risk factors The aim of this study was to assess the role of depression as a predictor of new onset of chronic migraine ( CM )  among persons with episodic migraine ( EM ) . The American Migraine Prevalence and Prevention ( AMPP ) study followed 24,000 persons with severe headache identified in 2004 . Using r and om-effects logistic regression , we modeled the probability that persons with EM in 2005 or 2006 would develop CM in the subsequent year . Depression was assessed in two ways , using a vali date d question naire ( PHQ-9 score ≥15 ) and based on self-reported medical diagnosis . Analyses were adjusted for multiple covariates including sociodemographics , body mass index , headache pain intensity , headache frequency , migraine symptom severity , cutaneous allodynia , acute medication overuse , anti-depressant use and anxiety . Of 6,657 participants with EM in 2005 , 160 ( 2.4 % ) developed CM in 2006 . Of 6,852 participants with EM in 2006 , 144 ( 2.2 % ) developed CM in 2007 . In fully adjusted models , PHQ-9 defined depression was a significant predictor of CM onset [ odds ratio ( OR ) = 1.65 , 95 % CI 1.12–2.45 ] . There was a depression-dose effect ; relative to participants with no depression or mild depression , those with moderate ( OR = 1.77 , 95 % CI 1.25–2.52 ) , moderately severe ( OR = 2.35 , 95 % CI 1.53–3.62 ) , and severe depression ( OR = 2.53 , 95 % CI 1.52–4.21 ) were at increased risk for the onset of CM . Among persons with EM  , depression was associated with an increased risk of CM after adjusting for sociodemographic variables and headache characteristics . Depression preceded the onset of CM and risk increased with depression severity suggesting a potentially causal role though reverse causality can not be excluded BACKGROUND Data for trends in prevalence of asthma , allergic rhinoconjunctivitis , and eczema over time are scarce . We repeated the International Study of Asthma and Allergies in Childhood ( ISAAC ) at least 5 years after Phase One , to examine changes in the prevalence of symptoms of these disorders . METHODS For the ISAAC Phase Three study , between 2002 and 2003 , we did a  cross-sectional question naire survey of 193,404 children aged 6 - 7 years from 66 centres in 37 countries , and 304,679 children aged 13 - 14 years from 106 centres in 56 countries , chosen from a r and om sample of schools in a defined geographical area . FINDINGS Phase Three was completed a mean of 7 years after Phase One . Most centres showed a change in prevalence of 1 or more SE for at least one disorder , with increases being twice as common as decreases , and increases being more common in the 6 - 7 year age-group than in the 13 - 14 year age-group , and at most levels of mean prevalence . An exception was asthma symptoms in the older age-group , in which decreases were more common at high prevalence . For both age-groups , more centres showed increases in all three disorders more often than showing decreases , but most centres had mixed changes . INTERPRETATION The rise in prevalence of symptoms in many centres is concerning , but the absence of increases in prevalence of asthma symptoms for centres with existing high prevalence in the older age-group is reassuring . The divergent trends in prevalence of symptoms of allergic diseases form the basis for further research into the causes of such disorders This cross-sectional clinical study was conducted in order to explore the relationship between atopic disorders and migraine . We evaluated 186 consecutive patients with migraine . Patients with a history of atopic disorders were compared with the others during headache-free intervals , for their headache characteristics , pulmonary test ( PFT ) performances and immunological screenings , through appropriate statistical methods . Of the patients with migraine , 77 ( 41.4 % ) reported at least one atopic disorder . PFT screening showed a general decreased pulmonary capacity and an important correlation between a positive history of atopic disorders and both increased eosinophil and IgE levels in headache-free periods . It should be discussed whether screening with PFT or immunological tests helps in early detection of progressive lung disease which might develop in these patients OBJECTIVE Clinical observation of a decrease in migraine frequency in patients with comorbid asthma taking montelukast  , a specific D4 leukotriene receptor antagonist , or zafirlukast , another leukotriene receptor antagonist , prompted us to explore a possible role for leukotriene modifiers in the treatment of migraine . ( A further prompt was a pharmacist colleague 's observation that a number of patients on these agents reported a decreased sensitivity to perfume triggers and improvement in migraine . ) BACKGROUND Nonsteroidal anti-inflammatory agents have been used widely in the treatment of migraine . Another class of anti-inflammatory agents , known as leukotriene modifiers , have not been studied to date with regard to their possible role in the treatment of migraine . The name " leukotriene is derived both from the parent molecule , which was originally isolated from leukocytes , and from its three double-bond carbon backbone or triene structure . Both prostagl and ins and leukotrienes are derived from the metabolism of arachidonic acid , with prostagl and ins coming off the cyclooxygenase pathway and leukotrienes derived via the enzyme 5-lipoxygenase . Both prostagl and ins and leukotrienes mediate inflammatory responses . The latter have been studied with regard to their role in the pathophysiology of asthma . METHODS A prospect i ve , open-label study evaluating the efficacy of montelukast , 10 mg or 20 mg , in the prophylaxis of  migraine in 17 patients is presented in this paper . All 17 patients completed the study that consisted of a 2-month baseline run-in period and a 3-month treatment phase . RESULTS Montelukast was extremely well tolerated , and no adverse events were reported by any of the patients . Fifty-three percent showed a reduction of greater than 50 % ( P<.025 ) in the frequency of severe attacks , with 41 % showing a reduction of greater than 60 % . Responders , including modest responders , rated the drug as excellent . CONCLUSIONS We conclude , given the limitations of an open-label study design and the small sample size , that montelukast shows potential as an effective , well-tolerated prophylactic agent in migraine . Double-blinded , placebo-controlled studies are warranted . In addition , the leukotrienes , as suggested previously in the literature , may play a role in the pathogenesis of migraine 
    Output:
    
If two conditions linked , once an individual undergo better control of asthma symptoms , might the excruciating migraine ease , too